Pipeline
“Let Food Be Thy Medicine”
We believe that modest changes in lifestyle can cure diseases and that nutrition is the main driver of our health condition. To achieve this, we use software-driven, digital health applications for precision therapy and lasting behavioral changes. For those afflicted by metabolic diseases, this can mean a life of health and joy.
At Perfood, our mission is to make this a concrete reality for people suffering from severe diseases. Our pipeline leverages our core expertise in personalized low glycemic nutrition, innovative and scientifically validated therapeutic features for each target indication and sophisticated digital products.
We follow a structured development process starting with early proof-of-concept studies using our research platform, Perfood Labs. After, we develop dedicated disease-specific digital therapeutics by involving medical practitioners, indications experts and patients. Pilot studies and randomized controlled clinical trials (RCTs) are subsequently conducted to investigate the products' clinical benefits. We embrace a continuous product improvement process in all of these areas.
Global health care costs¹
Prediction for digital health care globally²
1 in 3 adults
live with more than one chronic condition³
In the commercial stage
the product is already on the market.
Patients can access these
products via their doctor or
health insurances.
A pivotal phase is a clinical trial
(RCT) intended to demonstrate
and confirm the safety and
efficacy of a treatment and to
estimate the incidence of
common adverse effects.
The pilot phase is an initial small
-scale implementation that is
used to prove the viability of a
project idea.
when Perfood gathers information about the project,
sets up budget and forms precise project boundaries.
The goal of a discovery phase is to be able to make
data-driven decisions and reduce all risks connected
to product development.
Pipeline
Commercial
Migraine
Commercial
1 bn
globally affected
3 rd
most common disease
With sinCephalea, Perfood has developed a digital therapy for migraine. The product employs personalized low-glycemic diet to lower glycemic variation in combination with state-of-the-art non-pharmacological interventions and patient empowerment.
The product is a Class I Software as a Medical Device and has been admitted to the German DiGA registry for full reimbursement. Hence, sinCephalea is available to everyone with health insurance in Germany, approximately 80 million people.
Migraine affects more than 1 billion people worldwide. It is the sixth most common cause of disability and the third most frequent disease. Migraine affects predominantly women, particularly in their 30s, 40s and 50s. With a substantial number of patients being in their working age, Migraine also imposes a substantial economic disease burden on society. Migraine attacks can last up to 72 hours and completely derail a patients life.
Studies suggests that a central nervous energy deficiency due to insufficient energy supply by glucose plays a role in the development of migraine attacks. Effective regulation of glucose homeostasis in the brain is therefore a promising strategy for effective migraine prophylaxis.
Find out more about sinCephalea here:
www.sincephalea.de
Perfood Study personalized nutrition I
Perfood Study personalized nutrition II
Headache disorders
Migraine: A Review on Its History […]
Low glycemic index diet for migraine prophylaxis
Nutritional interventions […]
Pivotal
Type 2 Diabetes
Pivotal
537 m
globally affected
1 trill USD
health expenditures
With our novel digital therapeutic for type 2 diabetes - Glucura, Perfood has developed a digital intervention for patients who are normally only treated with oral anti-diabetic drugs. The core of this product is Perfood's technology for personalized low-glycemic diet. For Glucura specifically, completely novel algorithms to derive glycemic analyses with industry-leading accuracy have been developed. Glucura combines cutting-edge science with state-of-the-art lifestyle therapy such as inducing activity, sleep hygiene and patient-empowerment.
Approximately 537 million people worldwide are living with diabetes. The vast majority of those are diagnosed with Type 2 Diabetes. Almost one trillion USD or 9% of health expenditures for adults is being spent annually on treating diabetes. An additional estimated 541 million adults are at risk of developing Type 2 Diabetes. Complications are severe and diabetes is the leading cause for cardiovascular diseases, blindness, kidney failure and lower limb amputation in almost all high-income countries. More than that, Type 2 Diabetes substantially increases the risk of heart attack and stroke as well as the development of malignant conditions.
The product is currently in clinical evaluation. Learn more about Glucura here www.glucura.de
Discovery
Acne Vulgaris
Discovery
9.38%
globally affected
With approx. 9.38% of the global population being affected, Acne Vulgaris is the eight most common disease. Perfood is investigating the development of a digital therapy for the treatment of Acne Vulgaris.
Review of the epidemiology of acne vulgaris
PCOS
Discovery
4-20%
women globally affected
Perfood is developing a digital therapy based on personalized low glycemic diet to alleviate PCOS and find a regular menstarual cycle, reviving fertility. The project has been funded by the government of the state of Schleswig-Holstein in Germany with a non-refundable grant.
PCOS affects between 4-20% of women globally. It’s a multi-factorial disease, characterized by insulin-resistance, irregular ovulation, acne and excess hair growth. It’s one of the most common reasons for female infertility.
Psoriasis
Discovery
3%
globally affected
100bn USD
annual cost in US
Perfood has evaluated the potential benefit of its technology in patients with psoriasis together with a telemedicine partner. A digital therapeutics product is in the early stages of development.
More than 125 million people or around 3% of the global population suffer from Psoriasis. In the United States, 8 million people have the disease. Over 60% of patients report experiencing a severe impairment in their quality of life. The annual cost of Psoriasis in the USA alone is more than 100 billion USD, imposing a severe economic burden on society.
Food allergies
Discovery
2.25%
globally affected
Perfood has partnered with the Universities of Lubeck and Hohenheim in Germany and the Leibniz Center to develop novel diagnostics approaches from digital biomarkers as a foundation for accurate diagnosis, immediate intervention and therapies. The research & development project has been funded with a grant of 3 million € by the German Ministry of Education & Research.
Food allergies are affecting approx. 2.5% of the global population and up to 10% in some countries. Infants are especially impacted by food allergies. A core challenge in estimating prevalence of food allergies and treating the disease, is difficulty in diagnosing food allergies. Food allergies cause severe harm, substantially limiting a patient’s quality of life and causing potentially deadly allergic shocks.
Epidemiology of Food Allergy
Anaphylaxis Overview
Verbund gegen Nahrungsmittelunverträglichkeiten
Obesity
Discovery
13%
globally affected
Perfood has partnered with a European consortium of research institutions to develop novel treatments for shift workers with obesity. The project has been funded by the European Union with a grant of approximately 10 million Euro. Obesity is a substantial risk factor for the development of numerous diseases from cardiovascular to inflammatory, neurodegenerative and malignant dieseases. More than 650 million people and approximately 13% of the adult population worldwide have obesity. It is especially prevalent in shift workers.
Academic partners in this project include:
University of Vienna, FH Joanneum, Stichting Wageningen Research, Wageningen University, University of Bremen, TTZ Bremerhaven, Medical University Lodz, Medical University of Vienna, University of Copenhagen, Catholic University Leuven, Charité Berlin, Erasmus MC Rotterdam.
Colorectal cancer
Discovery
2 mil
diagnoses/year
40%
mortality rate
Perfood has partnered with the German Cancer Research Institute at the Helmholtz Society in Heidelberg, University of Lubeck and Hahn-Schickard to develop a digital therapy for patients with colon cancer. The project has been funded with approximately 10 million Euro in non-refundable grants by the German Ministry of Education and Research.
Colorectal cancer is the third most common cancer entity. Every year, approximately 2 million people are diagnosed with the disease. In the past 20 years, the trend has been that colorectal cancer has become more prevalent in younger people in their 20s and 30s. Mortality rates are at approximately 40%. Consequently, colon cancer is responsible for approximately 10% of all cancer-related deaths – just after lung cancer.
Mehr Lebensqualität & weniger Rückfälle bei Darmkrebs
Verbesserung der Lebensqualität Darmkrebspatienten
Colorectal cancer statistics
Global colorectal cancer burden
